tbuckley/cabot-search huggingface dataset:
OP0008 EULAR RECOMMENDATIONS FOR THE USE OF IMAGING IN THE DIAGNOSIS AND MANAGEMENT OF CRYSTAL-INDUCED ARTHROPATHIES IN CLINICAL PRACTICE
Authors: P. Mandl, M. A. D’agostino, V. Navarro-Compán, I. Gessl, G. Sakellariou, A. Abhishek, F. Becce, N. Dalbeth, H. K. Ea, E. Filippucci, H. B. Hammer, A. Iagnocco, A. De Thurah, E. Naredo, S. Ottaviani, T. Pascart, F. Perez-Ruiz, I. Pitsillidou, F. Proft, J. Rech, W. A. Schmidt, L. M. Sconfienza, L. Terslev, B. Wildner, P. Zufferey, G. Filippou
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. <h3>Objectives</h3> To formulate evidence-based recommendations on the use of imaging in the diagnosis and management of CiA. <h3>Methods</h3> Following EULAR standard operating procedures a task force of 25 stakeholders from 11 countries was created. Four systematic literature searches were performed in MEDLINE, EMBASE and CENTRAL to guide task force decisions, answering 14 research questions on the role of imaging in gout, calcium pyrophosphate and basic calcium phosphate deposition disease. Level of agreement (LoA) with each overarching principle and recommendation was assessed by numerical rating scale (0-10). <h3>Results</h3> Five overarching principles and 10 recommendations were produced on the role of imaging in making a diagnosis, monitoring, predicting, guiding intervention, and patient education in CiA (Table 1). Overall, the LoA for the recommendations was very high (8.5-9.9). <h3>Conclusion</h3> These are the first recommendations that encompass all common forms of CiA and guide the use of established imaging modalities in this disease group. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Peter Mandl: None declared, Maria-Antonietta D'Agostino: None declared, Victoria Navarro-Compán: None declared, Irina Gessl: None declared, Garifallia Sakellariou: None declared, Abhishek Abhishek: None declared, Fabio Becce Consultant of: Horizon, Grant/research support from: Siemens Healthineers, Nicola Dalbeth: None declared, Hang Korng Ea: None declared, Emilio Filippucci: None declared, Hilde Berner Hammer: None declared, Annamaria Iagnocco: None declared, Annette de Thurah: None declared, Esperanza Naredo: None declared, Sebastien Ottaviani: None declared, Tristan Pascart Consultant of: Novartis, Grant/research support from: Horizon Pharmaceuticals, Fernando Perez-Ruiz: None declared, IRENE Pitsillidou: None declared, Fabian Proft: None declared, Jürgen Rech: None declared, Wolfgang A. Schmidt: None declared, Luca Maria Sconfienza Consultant of: Esaote SPA, Samsung Medison, Fidia Farmaceutici, Pfizer, Novartis, Janssen Cilag, Abiogen, Bracco Imaging Italia, MSD, Merck Serono, Grant/research support from: Esaote SPA, Samsung Medison, Fidia Farmaceutici, Pfizer, Novartis, Janssen Cilag, Abiogen, Bracco Imaging Italia, MSD, Merck Serono, Lene Terslev: None declared, Brigitte Wildner: None declared, Pascal Zufferey: None declared, Georgios Filippou: None declared.
Erratum. Relationships of Serum 25-Hydroxyvitamin D Concentrations, Diabetes, Genetic Susceptibility, and New-Onset Chronic Kidney Disease. Diabetes Care 2022;45:2518–2525
Authors: Chun Zhou, Panpan He, Ziliang Ye, Yuanyuan Zhang, Yanjun Zhang, Sisi Yang, Qimeng Wu, Mengyi Liu, Jing Nie, Xianhui Qin
Journal: Diabetes Care (2023)

For the article cited above, diabetes status at baseline was incorrectly defined as “history of diabetes, fasting glucose ≥7.0 mmol/L, or HbA1c ≥6.5%.” The correct definition for diabetes status at baseline is “history of diabetes, glucose ≥7.0 mmol/L, or HbA1c ≥6.5%.” The text and tables have been revised to remove “fasting” from the definition. In Fig. 2, the number of participants with White ethnicity was incorrectly reported as 573; the correct number of participants with White ethnicity was 20,379. In Results, the typographical error “≥50 nmol/L (moderately deficient group)” has been corrected to “≥50 nmol/L (insufficient and above group).” These errors did not affect the data analyses or results of the article. The authors apologize for the errors. The online version of the article (https://doi.org/10.2337/dc22-1194) has been updated.
OP0083 ANAKINRA PLUS STANDARD OF CARE FOR THE REDUCTION OF HYPERINFLAMMATION AND RESPIRATORY DISTRESS IN PATIENTS WITH SARS-COV-2 INFECTION: A MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 2/3 TRIAL (ANA-COVID-GEAS STUDY)
Authors: P. Fanlo, B. Gracia Tello, E. Fonseca, J. Álvarez Troncoso, A. González, S. Prieto-González, M. Freire, A. Argibay, L. Pallares Ferreres, J. A. Todoli, M. Perez Conesa, S. Bujan Rivas, B. Ibañez
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and security of anakinra in patients with severe COVID-19 pneumonia and hyperinflammation are still unclear. <h3>Objectives</h3> The primary endpoint was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-to-treat-basis. <h3>Methods</h3> A multicentre, randomised, open-label, two-arm phase 2/3 trial was conducted at 12 hospitals in Spain. Adult patients with severe pneumonia were randomly assigned (1:1) to receive either usual standard of care plus anakinra (anakinra group) or usual standard of care alone (SoC group). Anakinra was given at a dose of 100 mg four times a day intravenously. The trial is registered with ClinicalTrials.gov; NCT04443881. <h3>Results</h3> Between 8 May 2020 and 1 March 2021, a total of 179 patients were randomly assigned to the anakinra group (n=92) or to the SoC group (n=87). The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups (77.1% for Anakinra group vs 85.9% for SoC group, risk ratio 0·90 [95% CI 0·77–1·04]; p=0·16). Anakinra did not result in any difference in time to mechanical ventilation (HR 1·72 [95% CI 0·82-3·62], p=0·14). There was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15 (RR 0·99 [95% CI 0·88–1·11]; p=1·00). <h3>Conclusion</h3> Anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone in hospitalised patients with severe COVID-19 <h3>References</h3> [1]Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. [2]Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
OP0031 CHILDREN WITH EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS HAVE ALTERATIONS IN B AND T FOLLICULAR CELL SUBSETS IN PERIPHERAL BLOOD AND A CYTOKINE PROFILE SUSTAINING B CELL ACTIVATION
Authors: C. Tomé, F. Oliveira-Ramos, R. Campanilho-Marques, A. F. Mourão, S. Sousa, C. Marques, A. T. Melo, R. L. Teixeira, A. P. Martins, S. Moeda, P. Costa Reis, R. Pinheiro Torres, M. J. Sousa Bandeira, H. Fonseca, M. Gonçalves, M. J. Santos, L. Graca, J. E. Fonseca, R. A. Moura
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Our group has recently demonstrated that extended oligoarticular and polyarticular JIA mostly evolve to a rheumatoid arthritis (RA)-like phenotype in adulthood. Disturbances in B cells, T follicular helper (Tfh) and T follicular regulatory (Tfr) cell immune responses are associated with RA pathogenesis, but their exact role in JIA development is poorly understood. <h3>Objectives</h3> The main goal of this study was to characterize the frequency and phenotype of B, Tfh and Tfr cells in peripheral blood and the cytokine environment present in circulation in children with with extended oligoarticular JIA (eoJIA) and polyarticular JIA (pJIA) when compared to healthy controls, children with persistent oligoarticular JIA (poJIA) and adult JIA patients. <h3>Methods</h3> Blood samples were collected from 105 JIA patients (children and adults) and 50 age- and gender-matched healthy individuals. Peripheral blood mononuclear cells were isolated and the frequency and phenotype of B, Tfh and Tfr cells were evaluated by flow cytometry. Serum levels of APRIL, BAFF, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-17A, IL-21, IL-22, IFN-γ, PD-1, PD-L1, sCD40L, CXCL13 and TNF were measured by multiplex bead-based immunoassay and/ or ELISA in all groups included. <h3>Results</h3> The frequency of B, Tfh and Tfr cells was similar between JIA patients and controls. Children with eoJIA and pJIA, but not poJIA, had significantly lower frequencies of plasmablasts, regulatory T cells and higher levels of Th17-like Tfh cells in circulation when compared to controls. Furthermore, APRIL, BAFF, IL-6 and IL-17A serum levels were significantly higher in pediatric eoJIA and pJIA patients when compared to controls. These immunological alterations were not found in adult JIA patients in comparison to controls. <h3>Conclusion</h3> Changes in B and Tfh cell subpopulations, but not in Tfr cells, were found in peripheral blood of children with eoJIA and pJIA when compared to controls. Our results suggest a potential role and/ or activation profile of B and Th17-like Tfh cells in the pathogenesis of eoJIA and pJIA, but not poJIA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Di-methylation of CD147-K234 Promotes the Progression of NSCLC by Enhancing Lactate Export
Authors: Ke Wang, Wan Huang, Ruo Chen, Peng Lin, Tao Zhang, Yun-Feng Ni, Hao Li, Jiao Wu, Xiu-Xuan Sun, Jie-Jie Geng, Yu-Meng Zhu, Gang Nan, Wei Zhang, Xi Chen, Ping Zhu, Huijie Bian, Zhi-Nan Chen
Journal: Cell Metabolism (2023)
POS0903 DIFFUSE GENERALIZED VENULITIS AS THE PRIMARY PATHOLOGY OF BEHÇET’S DISEASE: A COMPREHENSIVE MAGNETIC RESONANCE VENOGRAPHY STUDY
Authors: H. Karadeniz, M. Uçar, T. Mammadov, A. Avanoglu Guler, D. Yildirim, H. Küçük, B. Goker, M. A. Ozturk, A. Tufan
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Behçet's Disease (BD) is a chronic multisystem vasculitis that manifests with recurrent oral/genital ulcerations and destructive inflammation affecting eyes, central nervous system, and blood vessels. Venous thrombosis is observed in up to 40% of patients, however pathology of vein involvement in BD is poorly characterized <b>[1].</b> Recently, demonstration of wall thickening in posterior wall of common femoral vein with an ultrasound (US) was reported to be a reliable auxiliary diagnostic tool in BD. Magnetic resonance (MR) venography may give more comprehensive information about deep veins and adjacent tissues. <h3>Objectives</h3> In this study, we aimed to characterize vein involvement in BD and evaluate diagnostic utility of MR venography. <h3>Methods</h3> Sixty-five BD patients who fulfilled the International Study Group (ISG) criteria and 20 healthy control subjects were enrolled. BD patients were separated into two groups based on previous history of vascular involvement. Inferior vena cava (IVC), common iliac veins (CIV), external (EIV) and internal iliac veins (IVV), common femoral veins (CFV), femoral veins (FV), and greater saphenous veins (GSV) of BH patients and healthy controls were evaluated with MR venography and ultrasonography for the presence pathologic features, luminal thrombi, vessel wall changes and perivascular abnormalities. <h3>Results</h3> 33 vascular and 32 non-vascular BD patients (mean age 39.3±11.3 years and 48 [73.8%] male) were enrolled. MR venography revealed diffuse concentric thickening of the walls of IVC, CIV, EIV, IIV, CFV, FV and GSV in BD (healthy controls vs BD p&lt;0.05 for all the vein segments). <b>(Table 1).</b> There was no significant difference between vascular and non-vascular BD groups in terms of vein diameter and wall thicknesses, while both groups had significantly thicker veins than healthy controls (p&lt;0.05). US examination revealed similar results. MR venography provided additional information about veins and perivascular tissues like contrast enhancement, enlarged lymph nodes and seminal vesicle vascularization which were significantly more frequent in vascular BD than non-vascular BD and healthy controls. <h3>Conclusion</h3> The results of our study suggest that the involvement of the venous system is diffuse and generalized in BD, and demonstration of venulitis might help diagnose the disease. Further studies are needed to elucidate prognostic role of wall thickening, venulitis, in terms of anticipation of future thrombosis and treatment response. <h3>Reference</h3> [1]Y. Ozguler, M. Melikoglu, F. Çetinkaya, <i>et al.</i>The clinical course of the acute deep vein thrombosis of the legs in Behçet's syndrome Ann Rheum Dis. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0902 ANTI-SSA RO52 AND ANTI-RO60 AUTOANTIBODIES: ASSOCIATION WITH CLINICAL PHENOTYPES
Authors: C. Mazeda, N. Oliveira, C. Abreu, V. Fraga, A. Maduro, A. Saraiva, L. Inês, C. Campinho Ferreira, A. M. Gomes Correia, R. Nicolau, F. Farinha, I. Villanueva, D. Jesus, P. M. Azevedo Abreu, A. Neto, J. Silva-Dinis, A. Barcelos
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Anti-SSA autoantibodies can be differentiated according to their antigenic target proteins as anti-Ro60 (60 kDa) or anti-Ro52 (52 kDa). Anti-SSA(Ro60) are clearly associated with Connective Tissue Diseases (CTD), but the clinical significance of anti-SSA(Ro52) remains unclear. <h3>Objectives</h3> To analyze the disease phenotype of patients with anti-Ro52 and/or anti-Ro60. <h3>Methods</h3> Multicenter, cross-sectional study of anti-Ro52 and/or Ro60 positive patients followed at 10 Rheumatology centers from January 2018 until December 2021. Patients were categorised into 3 groups: group 1 (Ro52+/Ro60-); group 2 (Ro52-/Ro60+); group 3 (Ro52+/Ro60+). Antinuclear antibodies were evaluated by indirect immunofluorescence assay and further screened for anti-extractable nuclear antigen (ENA) antibodies. Demographics and clinical data were compared between the 3 groups, by patients' medical chart review. Univariate analysis was performed using chi-square, Fisher's exact or Kruskall-Wallis test. Subsequently, the Bonferroni test was used to identify intergroup differences (level of significance: p&lt;0.0167). Univariate logistic regression was used to calculate the odds ratio with a 95% confidence interval (CI). <h3>Results</h3> We included 776 patients [female: 83.1%; median age: 59 (46-71) years]. Groups 1, 2 and 3 comprised 31.1%, 32.6%, and 36.3% of the patients, respectively. Characteristics of the groups are presented in Table 1. Anti-Ro52 alone is more frequently associated with non-rheumatic diseases, older age, and men (p&lt;0.05). Among patients with CTD, the diagnosis of systemic lupus erythematosus is 3 and 2 times more prevalent in groups 2 and 3, respectively, than in group 1 [OR 2.8 (95% CI 1.60, 4.97),p=&lt;0.001; OR 2.2 (95% CI 1.28, 3.86), p=0.007]. In group 2, the diagnosis of undifferentiated connective tissue disease is more frequent than in the other groups. The presence of isolated Ro52+ is more frequently associated with inflammatory myositis than in group 2 [OR 0.09 (95% CI 0.01, 0.33), p=&lt;0.001] or group 3 [OR 0.08 (95% CI 0.01, 0.29), p=&lt;0.001]. Group 1 was also more frequently associated with arthritis (p=0.006), interstitial lung disease (p=0.002), and myositis (p=0.009). <h3>Conclusion</h3> Anti-Ro52+ alone is frequently found in patients with non-rheumatic diseases. In addition, anti-Ro52+ is also prevalent in patients with CTD and associated with clinical phenotypes that are different from anti-Ro60+. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0930 SUBCLINICAL SYNOVITIS OF THE KNEE REMAINED IN ONE-THIRD OF CASES IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TOTAL KNEE ARTHROPLASTY: MUSCULOSKELETAL ULTRASONOGRAPHY STUDY
Authors: Y. Miyoshi, E. Takamasu, R. Takada, Y. Nagase
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> There is no report investigating the prevalence, sites, and risk factors of knee synovitis in patients with rheumatoid arthritis (RA) after total knee arthroplasty (TKA). <h3>Objectives</h3> This study aimed to clarify the prevalence, anatomical distribution, and risk factors of knee synovitis in RA patients after TKA. <h3>Methods</h3> This study was a retrospective cross-sectional study. Subjects were patients who met the 2010 ACR/EULAR RA classification criteria and underwent TKA at Tokyo Metropolitan Tama General Medical Center. Knee joints on surgically treated sides were assessed by musculoskeletal ultrasonography (MSUS) from April 1, 2020, to March 31, 2022. Knee US-synovitis was defined as the presence of PD 2 or higher at joint synovium (suprapatellar bursa, medial/lateral parapatellar joint recess, medial/lateral tibiofemoral joint space). <h3>Results</h3> Forty-five patients with RA after TKA underwent MSUS, with a total of 71 knee joints (38 right, 33 left). Patient background: age (years) 74.4±10.0, female(%) 84%, disease duration (years) 20.6±10.4, TKA postoperative period (years) 5.7±4.0, ACPA positivity 77%, RF positivity 79%, DAS28(ESR) 3.17±1.03, mHAQ 0.8±0.8, PSL users 44%, MTX users 64%, csDMARDs users 87%, BioDMARDs users 44%, tsDMARDs users 0%, Knee injury and Osteoarthritis Outcome Score-pain (KOOS-P) 82.5±17.2. The number of joints with GS 2 or higher was more prevalent than that with PD 2 or higher (Figure 1). The number of post-TKA knee joints with PD 2 or higher was 18 (25.3%) out of 71. The knee joints assessed within one year from TKA were more likely to have joint synovitis detected by MSUS than those over one year (5 joints (62.5%) vs 13 (20.6%)). Fifteen (33.3%) patients had US-synovitis at post-TKA knee joints. There was no difference in disease activity scores (DAS28-CRP, DAS28-ESR, SDAI, CDAI), patient pain Visual Analogue Scale, or KOOS-P in patients with knee US-synovitis (n=15) compared with those without knee US-synovitis (n=30). There was no significant correlation between PD grades and KOOS-P (p=0.73). <h3>Conclusion</h3> Subclinical US-synovitis of the knee still remained in one-third of cases in patients with RA after TKA. US-synovitis at post-TKA knee joints did not correlate with knee pain scores. The knee prosthesis would have a protective effect on synovitis-induced pain at post-TKA knee joints in RA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0791-HPR NURSE EDUCATION ON METHOTREXATE FOR PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A SCOPING REVIEW TO INFORM EDUCATIONAL STANDARDS
Authors: A. Marques, C. Matos, P. Livermore, E. Nikiphorou, R. J. O. Ferreira
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patient education (PE) is a key role of nurses,[1] which includes providing information, training, and support about methotrexate (MTX), an anchor drug in rheumatology. However, there is wide variation in the access to rheumatology nurse consultations in Europe and no standard strategy about when, what, and how nurses should provide PE to these patients. <h3>Objectives</h3> The objective of this scoping review was to provide a comprehensive overview of the existing research on nurse education on MTX for children/youth and adults with Rheumatic and musculoskeletal diseases (RMDs). <h3>Methods</h3> We searched PubMed (MEDLINE), Scopus and Cochrane Database, and CINAHL complete, from inception until march of 2022. Articles on patient education with a focus on MTX exclusively were included. Two independent reviewers performed standardized data extraction and synthesis. <h3>Results</h3> From 292 references identified, 14 fulfilled the inclusion criteria (Figure 1). A Summary of study methods and results are presented in Table 1. <h3>Conclusion</h3> Through this scoping review, we identify that knowledge of MTX improves when education by nurses is provided. Patient education about MTX can be de delivered in different forms and can result in better satisfaction and adherence. More RCTs with powered samples are required. <h3>Reference</h3> [1]Bech B, et al. Annals Rheum Diseases 2020;79:61-68. <h3>Acknowledgements</h3> This study was funded by an unrestricted grant from medac, without any involvement in the scientific work. We thank the members of the RECONNECT-MTX group: Ágnes Ágoston-Szabó, Ana Isabel Rodriguez Vargas, Ana Pais, Ane Ludvigsen, Angela Camon, Claudia Paiva, Darja Batšinskaja, Ellen Moholt, Jana Melicharová, Karlien Claes, Khadija El Aoufy, Kristina Buerki, Marie-Louise Karlsson, Mikaella Konstantinou, Myrto Nikoloudaki, Souzi Makri, Ulrike Erstling, Una Martin. <h3>Disclosure of Interests</h3> Andrea Marques: None declared, Cristiano Matos: None declared, Polly Livermore Consultant of: Nordic Pharma, Grant/research support from: GOSH NIHR BRC and NIHR Personal Fellowship, Elena Nikiphorou Speakers bureau: Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, Lilly, Fresenius, Paid instructor for: Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, Lilly, Fresenius, Grant/research support from: Lilly, Pfizer, Ricardo J. O. Ferreira Speakers bureau: MSD, Sanofi, Amgen, Roche, Paid instructor for: UCB, Consultant of: medac, abbvie, roche, Sanofi, Amgen, Grant/research support from: Abbvie, medac, Amgen.
POS0775 ASSESSMENT OF SCHOOLING OUTCOMES OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
Authors: M. Ghali, D. Khalifa, M. Cheour, R. Fakhfakh, N. El Amri, K. Baccouch, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common inflammatory arthropathy in childhood. It can often be disabling, have an impact on the child's integration, and affect school attendance to varying degrees. <h3>Objectives</h3> The objective of this study was to assess the impact of juvenile idiopathic arthritis (JIA) on children's educational outcomes. <h3>Methods</h3> This is a cross-sectional monocentric study including school-age children with JIA diagnosed according to the International League of Associations of Rheumatology (ILAR) classification criteria. Data were collected for all children on their school level, school difficulties, attendance, and absenteeism. Academic failure was defined by either dropping out of school or grade retention. To evaluate disease activity we used the Disease activity score (DAS-28) for oligoarticular and polyarticular forms, and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score for axial forms. The Childhood Health Assessment Questionnaire (C-HAQ) was used to assess functional disability. <h3>Results</h3> Thirty-six patients were enrolled. The average age was 13.5 ± 5.9 with a female percentage of 55.6 %. The polyarticular form was the most frequent (52.8%) meanly seronegative, followed by the Oligoarticular form (13.9%), then the enthesitis-related form (12.4%). None of our patients was illiterate. Eight children (22.2%) dropped out of school because of their functional disability. Students with JIA who attended school had an absenteeism rate of 67.8%. Slightly more than half of the JIA patients (57.1%) failed at least one grade. Academic failure was associated with a high disease activity (p=0.003), the presence of joint deformities (p=0.002), a high C-HAQ score (p=0.01), and an erythrocyte sedimentation rate: ESR ≥100 mm/h (p=0.02). The absenteeism rate was associated with rural origin (p=0.004), pain level (p=0.02), high disease activity (p=0.01), hip involvement (p=0.001), and a high C-HAQ score (p=0.03). <h3>Conclusion</h3> Our study shows that the schooling of children with JIA was negatively influenced by this disease. Proper control of the disease activity and inflammation will guarantee better school attendance and increase academic performance. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.